Home
Publication
Commentaries
A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

3 min read
January 14, 2020
cell

‍

Matheis F, Muller PA, Graves CL, Gabanyi I, Kerner ZJ, Costa-Borges D, Ahrends T, Rosenstiel P, Mucida D.
Adrenergic Signaling in Muscularis Macrophages Limits Infection-Induced Neuronal Loss.
Cell. 2020 Jan.

A recent study, freshly published in Cell by a group of researchers at Rockefeller University, demonstrates that enteric infections cause rapid neuronal loss via the two non-canonical inflammasomes Nlrp6 and Casp11. This was elegantly demonstrated by infecting conditional Knockout mice with an attenuated strain of Salmonella enterica and, subsequently, quantifying the numbers of enteric neurons.

‍

In addition, researchers found that resident macrophages rapidly respond to enteric pathogens by activating the β2-adrenergic receptor (β2-AR) signaling that, in turn, triggers the synthesis of neuroprotective polyamines, thereby limiting neuronal loss. These findings suggest an extremely sophisticated interplay between enteric neurons and macrophages similar to what has been already described for the central nervous system.

Related products

Catalogue product

No items found.

Customized product

Tissue-specific KO mouse

Use tissue- or cell-specific conditional Knockout mouse models to bypass embryonic lethality, compensatory mechanisms, complex phenotypes, etc.

Time-dependent KO mouse

Use an inducible conditional Knockout mouse to age-dependently inactivate your gene, and to enable studies at defined development stages or on age-related diseases.

Other commentaries
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized genO-BRGSF-HIS preclinical model

CRS in genO-BRGSF-HIS

7 min read
-
Feb 2024
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

10 min read
-
Dec 2023
Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

7 min read
-
Dec 2023
Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

3 min read
-
Oct 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

3 min read
-
Mar 2023
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

3 min read
-
Nov 2022
Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

4 min read
-
Nov 2022
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

6 min read
-
Jun 2022
Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

6 min read
-
Jun 2022
Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

5 min read
-
May 2022
Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

3 min read
-
Apr 2022
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

3 min read
-
Mar 2022
An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read
-
Mar 2022
Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

5 min read
-
Mar 2022
Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

8 min read
-
Jan 2022
Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

8 min read
-
Nov 2021
NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

3 min read
-
Nov 2021
A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

3 min read
-
Nov 2021
Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

6 min read
-
Nov 2021
Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

5 min read
-
Sep 2021
The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

4 min read
-
Sep 2021
Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

6 min read
-
Aug 2021
Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

5 min read
-
Aug 2021
New doors to potential novel treatments for obesity

Customized mouse model

3 min read
-
Jun 2021
Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

3 min read
-
Apr 2021
A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

8 min read
-
Feb 2021
Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

4 min read
-
Nov 2020
A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

3 min read
-
Apr 2020
HSC-derived cell fate tracking

Customized mouse model

3 min read
-
Mar 2020
A VISTA on naive T cell fate

Humanized ICP mouse

3 min read
-
Feb 2020
A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

3 min read
-
Oct 2019
6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

6 min read
-
Aug 2019
Show all commentaries
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe

Mouse
Customized model